InvestorIdeas.com is pleased to provide investors following the Biotech sector resources including news, industry research and a list of public companies in the sector. The Biotech sector has attracted serious investor attention with stocks realizing one-day gains not seen in the market for years. On April 26th, OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) went up $52 as it announced that a Phase III study of Tarceva(TM) (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva(TM) living longer than those in the placebo arm of the study. This is an indicator of the urgent need to find therapies and solutions in cancer treatment as the lifetime probability of being diagnosed with cancer, for both men and women, has increased to dramatic rates.
